Pfizer: Firing On All Cylinders

Louis Gerard 3.95K Followers Follow Summary Pfizer (PFE) remains a strong buy as guidance is reaffirmed and raised, with acquired assets compounding at 18% operationally. PFE's pipeline strength is evident, especially in obesity (berobenatide) and Vyndamax, providing a bridge over the 2028 LOE trough. Valuation is highly attractive: P/E of 9.11, EV/EBITDA of 8.29, and a 6.19% dividend yield, with disciplined capital allocation. Key risks include margin pressure and Eliquis pricing reversals, but cost programs and pipeline momentum support the bullish thesis. Veronique D/iStock Editorial via Getty Images Introduction It has been a while since I last covered Pfizer ( PFE ), one of the names I’ve most covered on Seeking Alpha. I was arguing back then that t he setup This article was written by Louis Gerard 3.95K Followers Follow As a detail-oriented investor with a strong foundation in finance and business writing, I focus on analyzing undervalued and disliked companies or industries that have strong fundamentals and good cash flows. I have a particular interest in sectors such as Oil&Gas and consumer goods. Basically, anything that has been unloved for unjustified reasons that could offer substantial returns. Energy Transfer is one of those companies that I came across when no one wanted to touch it and now I can't resolve myself to sell it. I will always focus more on long-term value investing but I can sometimes lose myself in possible deal arbitrage such as with Microsoft/ Activision Blizzard, Spirit Airlines/Jetblue (that one still hurts), and Nippon/U.S. Steel (perfect exit at $50.19). I tend to shun businesses that I can't understand either high-tech or certain consumer goods such as fashion (give me a Levi's jeans). I don't understand why anyone would invest in cryptocurrencies as well. Through Seeking Alpha, I aim to connect with like-minded investors, share insights, and build a collaborative community of individuals seeking superior returns and informed decision-making, currently on a quest to review every public company. Analyst’s Disclosure: I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.